ROSACEA DRUG TRIALS

CollaGenex Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration has approved two phase 3 clinical trials of Col-101, a once-daily, modified-released formulation of doxycycline, 40 mg, for treatment of rosacea.

Related Videos
Related Content

Highlights from AAD 2023

March 23rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Pregnant Women with Skin Conditions May Require Dermatologic Intervention

March 23rd 2023

Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 23rd 2023

Highlights from AAD 2023

March 23rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Pregnant Women with Skin Conditions May Require Dermatologic Intervention

March 23rd 2023

Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 23rd 2023

Highlights from AAD 2023

March 23rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Pregnant Women with Skin Conditions May Require Dermatologic Intervention

March 23rd 2023

Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.